Micromet (MITI) Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients
More News related to MITI
- Micromet to Present at The Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
- Micromet, Inc. Replay of Third Quarter 2009 Financial Results Conference Call Now Available
- Micromet, Inc. Reports Third Quarter 2009 Financial Results
- Micromet Buys Out MedImmune's Remaining Rights to Blinatumomab
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Corporate News
- StemCells (STEM) Begins Recruitment for HuCNS-SC Phase I
- China Green Agriculture (CGA) Enters into $20M Direct Placement
- Seattle Genetics (SGEN) and Agensys Announce Expansion of ADC Collaboration
- Cumberland Pharma (CPIX) Announces Positive Top-Line Results of Caldolor Injection
- Raytheon (RTN) Awarded $241.3M U.S. Navy Contract for DDG 1000 Architect Software
Micromet, Inc. (Nasdaq: MITI) last week presented an update from an ongoing clinical study of the BiTE(R) antibody blinatumomab (MT103) for non-Hodgkin's lymphoma (NHL) at the 14th Congress of the European Hematology Association (EHA), held June 4 to 7 in Berlin, Germany. Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy cancer cells.
The poster presentation gave an update of an ongoing phase 1 trial of blinatumomab in relapsed NHL patients including a follow-up on response duration as well as pharmacodynamic activity(1). A dose-dependent clinical activity has been observed in these patients including partial and complete responses following treatment with single agent blinatumomab(2).
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
